Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
53.79
-0.11 (-0.20%)
At close: Aug 13, 2025, 4:00 PM
54.00
+0.21 (0.39%)
After-hours: Aug 13, 2025, 6:20 PM EDT
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $378.05M in the quarter ending June 30, 2025, a decrease of -4.07%. This brings the company's revenue in the last twelve months to $1.52B, up 5.75% year-over-year. In the year 2024, Lantheus Holdings had annual revenue of $1.53B with 18.32% growth.
Revenue (ttm)
$1.52B
Revenue Growth
+5.75%
P/S Ratio
2.44
Revenue / Employee
$1,881,996
Employees
808
Market Cap
3.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.53B | 237.48M | 18.32% |
Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LNTH News
- 6 days ago - Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Lantheus Holdings: Reassessing The Buy Thesis - Seeking Alpha
- 7 days ago - Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent - GlobeNewsWire
- 22 days ago - Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D - GlobeNewsWire
- 23 days ago - Lantheus Holdings: Forget The Short Term Noise - Seeking Alpha
- 4 weeks ago - Why Is Lantheus Stock Trading Lower On Wednesday? - Benzinga
- 6 weeks ago - Lantheus Seems Worth The (Very Real) Risks - Seeking Alpha
- 2 months ago - Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting - GlobeNewsWire